JP2019534251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534251A5 JP2019534251A5 JP2019516622A JP2019516622A JP2019534251A5 JP 2019534251 A5 JP2019534251 A5 JP 2019534251A5 JP 2019516622 A JP2019516622 A JP 2019516622A JP 2019516622 A JP2019516622 A JP 2019516622A JP 2019534251 A5 JP2019534251 A5 JP 2019534251A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- taxane
- body surface
- surface area
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 32
- 229940123237 Taxane Drugs 0.000 claims 25
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 25
- 239000003112 inhibitor Substances 0.000 claims 20
- 229940124647 MEK inhibitor Drugs 0.000 claims 18
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 18
- 229960001592 paclitaxel Drugs 0.000 claims 12
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 12
- 229960002271 cobimetinib Drugs 0.000 claims 11
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical group OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 11
- 206010006187 Breast cancer Diseases 0.000 claims 10
- 208000026310 Breast neoplasm Diseases 0.000 claims 10
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 10
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 6
- 229930012538 Paclitaxel Natural products 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229960003852 atezolizumab Drugs 0.000 claims 4
- 239000012830 cancer therapeutic Substances 0.000 claims 3
- 239000000890 drug combination Substances 0.000 claims 3
- 229940126585 therapeutic drug Drugs 0.000 claims 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401638P | 2016-09-29 | 2016-09-29 | |
| US62/401,638 | 2016-09-29 | ||
| PCT/US2017/053954 WO2018064299A1 (en) | 2016-09-29 | 2017-09-28 | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534251A JP2019534251A (ja) | 2019-11-28 |
| JP2019534251A5 true JP2019534251A5 (enExample) | 2020-11-12 |
Family
ID=60186360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516622A Pending JP2019534251A (ja) | 2016-09-29 | 2017-09-28 | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤、及びタキサンを用いた併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190209701A1 (enExample) |
| EP (1) | EP3518970A1 (enExample) |
| JP (1) | JP2019534251A (enExample) |
| KR (1) | KR20190061030A (enExample) |
| CN (1) | CN109862917A (enExample) |
| AU (1) | AU2017335839A1 (enExample) |
| BR (1) | BR112019005815A2 (enExample) |
| CA (1) | CA3038671A1 (enExample) |
| IL (1) | IL265668A (enExample) |
| MX (1) | MX2019003603A (enExample) |
| TW (1) | TW201815419A (enExample) |
| WO (1) | WO2018064299A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116327953A (zh) | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
| AU2019342133B8 (en) * | 2018-09-21 | 2025-08-07 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| US20210348238A1 (en) * | 2018-10-16 | 2021-11-11 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| WO2020131765A1 (en) * | 2018-12-19 | 2020-06-25 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor |
| WO2021257503A1 (en) * | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| BR9813365A (pt) | 1997-12-05 | 2004-06-15 | Scripps Research Inst | Método para produção e humanização de um anticorpo monoclonal de rato |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8146000B1 (en) | 2005-10-07 | 2012-03-27 | Goodwell Technologies, Inc. | Integrated transactional workflows distributed across multiple contact centers |
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
| BR122022000334B1 (pt) * | 2011-08-01 | 2023-03-21 | Genentech, Inc | Composição farmacêutica compreendendo um antagonista de ligação ao eixo pd-1 e um inibidor de mek |
| HK1206605A1 (en) | 2012-08-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| BR112015008113B1 (pt) | 2012-10-12 | 2022-05-24 | Exelixis, Inc. | Novo processo para preparar compostos para uso no tratamento de câncer |
| MY189089A (en) * | 2013-12-17 | 2022-01-25 | Genentech Inc | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| CN116327953A (zh) * | 2015-06-17 | 2023-06-27 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法 |
-
2017
- 2017-09-28 MX MX2019003603A patent/MX2019003603A/es unknown
- 2017-09-28 CA CA3038671A patent/CA3038671A1/en not_active Abandoned
- 2017-09-28 CN CN201780065799.4A patent/CN109862917A/zh active Pending
- 2017-09-28 WO PCT/US2017/053954 patent/WO2018064299A1/en not_active Ceased
- 2017-09-28 JP JP2019516622A patent/JP2019534251A/ja active Pending
- 2017-09-28 KR KR1020197011867A patent/KR20190061030A/ko not_active Ceased
- 2017-09-28 EP EP17791212.8A patent/EP3518970A1/en not_active Withdrawn
- 2017-09-28 AU AU2017335839A patent/AU2017335839A1/en not_active Abandoned
- 2017-09-28 BR BR112019005815A patent/BR112019005815A2/pt not_active Application Discontinuation
- 2017-09-28 TW TW106133384A patent/TW201815419A/zh unknown
-
2019
- 2019-03-27 US US16/366,411 patent/US20190209701A1/en not_active Abandoned
- 2019-03-27 IL IL265668A patent/IL265668A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534251A5 (enExample) | ||
| JP2018108086A5 (enExample) | ||
| JP2018184417A5 (enExample) | ||
| JP2019524820A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| JP2020002171A5 (enExample) | ||
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| JP2012525853A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2018506550A5 (enExample) | ||
| JP2019516733A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| IL300151A (en) | Combinations for the treatment of cancer | |
| JP2020521797A5 (enExample) | ||
| JP2016503413A5 (enExample) | ||
| JP2015530867A5 (enExample) | ||
| JP2017160178A5 (enExample) | ||
| RU2015151454A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АФУКОЗИЛИРОВАННОГО АНТИТЕЛА К CD20 В СОЧЕТАНИИ С КОНЪЮГАТОМ АНТИТЕЛО К CD79b-ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2018530578A5 (enExample) | ||
| RU2012131411A (ru) | АНТИТЕЛА ПРОТИВ Bv8 И ИХ ПРИМЕНЕНИЕ | |
| JP2020517696A5 (enExample) | ||
| JP2018529661A5 (enExample) |